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InsBACKGROUND Cardiac manifestations of neonatal lupus (cardiac NL) include congenital heart block and
cardiomyopathy. Several candidate biomarkers were evaluated in cases at risk for cardiac NL on the basis of potential
roles in inﬂammation, ﬁbrosis, and cardiac dysfunction: C-reactive protein (CRP); NT-pro-B-type natriuretic peptide
(NT-proBNP); troponin I; matrix metalloproteinase (MMP)-2; urokinase plasminogen activator (uPA); urokinase
plasminogen activator receptor (uPAR); plasminogen; and vitamin D.
OBJECTIVES Identiﬁcation of maternal and fetal biomarkers associated with development and morbidity of cardiac NL
should provide clues to pathogenesis with translational implications for management.
METHODS Cord (139) and maternal (135) blood samples collected during pregnancies at risk for cardiac NL were
available for study. Levels of cord and maternal CRP, cord NT-proBNP, and cord troponin I were evaluated using
multiplex assays. Cord and maternal vitamin D were assessed by liquid chromatography-mass spectrometry. MMP-2, uPA,
uPAR, and plasminogen were evaluated using ELISA.
RESULTS Cord CRP, NT-proBNP, MMP-2, uPA, uPAR, and plasminogen levels were higher in cardiac NL-affected fetuses
than in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL development,
and medications taken during pregnancy. These biomarkers were positively associated with a disease severity score
derived from known risk factors for mortality in cardiac NL. Maternal CRP and cord troponin I levels did not differ be-
tween the groups. Cord and maternal vitamin D levels were not signiﬁcantly associated with cardiac NL, but average
maternal vitamin D level during pregnancy was positively associated with longer time to postnatal pacemaker placement.
CONCLUSIONS These data support the association of fetal reactive inﬂammatory and ﬁbrotic components with
development and morbidity of cardiac NL. Following CRP and NT-proBNP levels after birth can potentially monitor
severity and progression of cardiac NL. MMP-2 and the uPA/uPAR/plasminogen cascade provide therapeutic targets to
decrease ﬁbrosis. Although decreased vitamin D did not confer increased risk, given the positive inﬂuence on postnatal
outcomes, maternal levels should be optimized. (J Am Coll Cardiol 2015;66:930–9) © 2015 by the American College of
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DCM = dilated cardiomyopathy
EFE = endocardial
ﬁbroelastosis
GA = gestational age
MMP = matrix
metalloproteinase
NL = neonatal lupus
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931N eonatal lupus (NL) is a form of passively ac-quired autoimmunity, typically presentingas cardiac and/or cutaneous disease. The
former disease is clinically identiﬁed as congenital
heart block and/or cardiomyopathy (1,2). Injury to
the developing heart is postulated to occur secondary
to a proinﬂammatory and proﬁbrotic cascade initiated
following transplacental passage of maternal autoan-
tibodies to SSA/Ro and/or SSB/La ribonucleoproteinsSEE PAGE 940 RRNL = Research Registry for
Neonatal Lupus
SLE = systemic lupus
erythematosus
SS = Sjögren’s syndrome
uPA = urokinase plasminogen
activator
uPAR = urokinase plasminogen
activator receptor(2–4). Detection occurs most often between the gesta-
tional ages (GA) of 16 and 24 weeks of pregnancy (2).
Cardiac NL is associated with a signiﬁcant risk of mor-
tality (17%; most occurring in the fetal or neonatal
period) and morbidity (70% of survivors require pace-
maker placement) (5,6). The case fatality rate is great-
est in those with lower ventricular rates in utero and
disease that extends beyond the atrioventricular (AV)
node, such as endocardial ﬁbroelastosis (EFE), dilated
cardiomyopathy (DCM), and hydrops fetalis (5,6). The
estimated risk of cardiac NL in anti-SSA/Ro–positive
mothers with no prior affected pregnancies is approx-
imately 2% and is 6- to 10-fold higher following a pre-
viously affected child (7–10). The low penetrance rate
suggests that anti-SSA/Ro antibodies are necessary
but insufﬁcient for the development of disease and
that fetal reactivity and in utero environment are
likely contributory.
Several of the candidate biomarkers that have been
associated with inﬂammation, ﬁbrosis, and heart
dysfunction may play a role in the development,
progression, and severity of cardiac NL. C-reactive
protein (CRP), a sensitive marker of inﬂammation,
has been associated with coronary heart disease in
adults and is elevated in fetal hypoxia and neonatal
sepsis (11,12). N-terminal pro-B-type natriuretic
peptide (NT-proBNP) is used in screening and diag-
nosis of congestive heart failure in adults and has
been associated with fetal heart dysfunction in um-
bilical cord blood and amniotic ﬂuid (13,14). Tro-
ponin I is a sensitive and speciﬁc marker for
myocardial damage and necrosis (15). Elevated con-
centrations of matrix metalloproteinase (MMP)-2, a
proinﬂammatory and proﬁbrotic factor that activates
transforming growth factor (TGF)-b, have been found
in adult heart failure patients (16). MMP-2 is stimu-
lated by urokinase plasminogen activator/urokinaseAmerica LFA Lifeline Program. All other authors have reported that they ha
paper to disclose.
Listen to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
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dependent plasminogen activation and
plasmin generation, which have been associ-
ated with cardiac NL in a previous univariate
analysis (17). Vitamin D has been shown to act
as a negative regulator in TGF-b signaling and
ﬁbrosis and has been associated with cardiac
inﬂammation, ﬁbrosis, and dysfunction in
rats (18,19). Recently, on the basis of indirect
evidence and seasonal time of the vulnerable
period during pregnancy, it was speculated
that vitamin D levels might be decreased in
mothers during pregnancies of cardiac NL
children (10).
Identiﬁcation of fetal and maternal bio-
markers that associate with the development
and morbidity of cardiac NL should provide
clues to pathogenesis, with translational im-
plications for management. Accordingly, this study
used a U.S.-based cohort of anti-SSA/Ro-exposed
cardiac NL-affected and -unaffected pregnancies to
evaluate candidate biomarkers in umbilical cord
blood of fetuses and in maternal blood from the time
of pregnancy. It was previously reported that CRP,
NT-proBNP, and troponin do not cross the placenta;
thus, increases in cord blood biomarkers can be
attributed to fetal production (20–22). The higher
masses of MMP-2 (74 kDa), uPA (49 kDa), uPAR (37
kDa), and plasminogen (91 kDa) likely preclude
placental transfer, and active transport of markers of
collagen metabolism has not been reported in
humans (23). Furthermore, MMP-2 and the plasmin-
ogen activators are expressed in placental tissue, and
fetal and placental concentrations of uPA and uPAR
are signiﬁcantly higher than in maternal blood
(24,25). Fetal vitamin D is entirely dependent on
maternal stores and, because 25(OH) vitamin D dif-
fuses across the placenta, cord and maternal blood
levels correlate closely (26).
METHODS
STUDY POPULATION. Subjects were identiﬁed from
the Research Registry for Neonatal Lupus (RRNL),
described elsewhere (27). The Institutional Review
Board of the New York University School of Medicine
approved the evaluation of deidentiﬁed information.
Brieﬂy, enrolled mothers have anti-SSA/Ro and/orve no relationships relevant to the contents of this
ntin Fuster.
2015, accepted June 15, 2015.
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Maternal and cord blood collected during the time of
a cardiac NL or unaffected pregnancy were analyzed.
Cardiac NL was deﬁned as previously described (6).
Pregnancies complicated by ﬁrst-degree block or
transient sinus bradycardia were excluded from the
dichotomous analyses comparing cardiac NL with
unaffected fetuses because their benign features
could dilute the effects of the more characteristic se-
vere disease. A severity score of fetal outcomes was
generated to associate potential biomarkers with dis-
ease morbidity (Table 1). For this score, sinus brady-
cardia and ﬁrst-degree block cases were included as a
potential outcome along the spectrum of cardiac NL.
The extreme end of the spectrum included features
associated with an increased risk of morbidity and
mortality, such as lower fetal ventricular nadir (which
requires earlier pacing) and extranodal disease
(5,6,28). Cardiac NL-affected individuals were con-
tacted between September 1, 2011, and June 1, 2014, to
evaluate the need for cardiac medications (beta-
blockers, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, or digoxin).
SERUM ANALYSIS. CRP, NT-proBNP, and troponin I
were evaluated using commercial Luminex assays
(human cardiovascular disease panel 3, HCVD3MAG-
67K, and panel 1, HCVD1MAG-67K; Millipore, Bill-
erica, Massachusetts). ELISA was used to assess levels
of MMP-2 according to themanufacturer’s instructions
(R&D Biosystems, Minneapolis, Minnesota). Total
25(OH) vitamin D was assessed by quantitative high-
performance liquid chromatography-tandem mass
spectrometry.
STATISTICAL ANALYSIS. Univariate and multivar-
iate analyses were applied to identify associations
among serum biomarkers and outcome responses
including cardiac NL, fetal echocardiographic EFE,TABLE 1 Severity Scores for Potential Outcomes in
Anti-SSA/Ro-Exposed Fetuses
Outcome Severity Score
Unaffected 0
Sinus bradycardia (transient) 1
First-degree AV block 2
Advanced AV block, no PPM at 6 months 5
Advanced AV block, PPM placed by 6 months 6
Advanced AV block, PPM placed by 1 week 8
1 extranodal manifestation 14
>1 extranodal manifestation 16
Death 20
Advanced AV block ¼ second- or third-degree heart block; AV ¼ atrioventricular;
PPM ¼ permanent pacemaker; extranodal manifestation ¼ endocardial ﬁbroelas-
tosis, dilated cardiomyopathy, or hydrops fetalis.DCM, and hydrops; requirement of and age at pace-
maker placement; requirement of cardiac medica-
tions on long-term follow-up; death; and severity
score. Cord blood uPA, uPAR, and plasminogen
levels, which were previously reported in univariate
analysis with cardiac NL by Briassouli et al. (17), were
also included in the additional analyses. Logistic
regression was applied to binary outcomes, and or-
dinary linear regression was applied to continuous
outcomes. In univariate analysis, each biomarker, as a
predictor, was regressed on each outcome. In multi-
variate analysis, both predictors and confounders
were regressed on the outcomes in a variable selec-
tion procedure. Models with a p value of <0.05 and
confounders with a p value of <0.2 were selected for
the ﬁnal multivariate analysis. Confounders included
maternal use of ﬂuorinated steroids (which cross the
placenta, potentially affecting both the fetal and
maternal inﬂammatory response); nonﬂuorinated
steroids (which are inactivated by the placenta and
affect only the maternal inﬂammatory response);
hydroxychloroquine; and/or intravenous immuno-
globulin (IVIg) during pregnancy; Caucasian race;
maternal diagnosis of systemic lupus erythematosus
(SLE) and/or Sjögren’s syndrome (SS); child’s sex; GA
20 weeks occurring in winter; GA at delivery; and age
of cardiac NL individual at long-term follow-up. Re-
sults for CRP and NT-proBNP showed right skewness
of their empirical distribution, and natural logarithms
were used for normalization.
RESULTS
PATIENT DEMOGRAPHICS AND OUTCOMES. In total,
cord blood samples were obtained from 139 anti-SSA/
Ro-exposed fetuses, 59 (42%) with cardiac NL, 75
(54%) who were unaffected (including 7 with cuta-
neous NL), 2 (1%) with ﬁrst-degree heart block, and
3 (2%) with sinus bradycardia during pregnancy.
Maternal blood samples during pregnancy were
obtained in 135 cases; 54 (40%) resulting in cardiac
NL-affected fetuses, 76 (56%) in unaffected fetuses
(10 with cutaneous NL), 2 (1%) with ﬁrst-degree
heart block, and 3 (2%) with sinus bradycardia.
Demographics, medications used, and fetal outcomes
are shown in Table 2.
C-REACTIVE PROTEIN. Median cord CRP levels were
higher in cardiac NL fetuses than in unaffected
cases (Table 3). Log-transformed levels of cord CRP
were positively associated with cardiac NL in uni-
variate (odds ratio [OR]: 1.57; OR per SD: 1.90;
p ¼ 0.009) and multivariate (OR: 1.50; OR per SD: 1.78;
p ¼ 0.09) analyses (Central Illustration). Log cord CRP
was signiﬁcantly associated with severity score in
TABLE 2 Clinical and Demographic Characteristics of Anti-SSA/Ro-Exposed Cardiac NL and Unaffected Cases
Available Cord Blood Available Maternal Blood During Pregnancy
Cardiac NL
(n ¼ 59)
Unaffected
(n ¼ 75) p Value
Cardiac NL
(n ¼ 54)
Unaffected
(n ¼ 76) p Value
Maternal caucasian race 44 (75) 48/73 (66) 0.34 40 (70) 55 (72) 1.00
Maternal diagnosis
Asymptomatic/UAS 30 (51) 29 (39) 0.17* 24 (44) 34 (45) 1.00*
SS 19 (32) 24 (32) 19 (35) 21 (28)
SLE 3 (5) 7 (9) 4 (7) 6 (8)
SLE and SS 6 (10) 12 (16) 6 (11) 15 (20)
Unknown 1 (2) 3 (4) 1 (2) 0 (0)
Maternal anti-SSB/Laþ 32/56 (57) 29/49 (59) 0.85 30/51 (59) 33/53 (62) 0.84
Maternal medications during pregnancy
Fluorinated steroids 39/58 (67) 6/67 (9) <0.001 38/53 (72) 5/72 (7) <0.001
Nonﬂuorinated steroids 5/58 (9) 11/67 (16) 0.28 4/53 (8) 10/71 (14) 0.39
IVIg 6/58 (10) 17 (23) 0.07 3/53 (6) 21/76 (28) 0.02
Hydroxychloroquine 5/57 (9) 26/67 (39) <0.001 8/53 (15) 37/71 (52) <0.001
Child female sex 34/58 (59) 35/73 (48) 0.29 30/52 (58) 29/68 (43) 0.14
GA 20 weeks during winter 13 (22) 21/70 (30) 0.32 12 (22) 18/70 (26) 0.68
GA (weeks) at time of birth 36.7  2.1 38.3  1.7 <0.001 36.5  3.0 38.4  1.78 <0.001
Fetal echo EFE 11/53 (21) 13/48 (27)
Fetal echo DCM 4/50 (8) 3/47 (6)
Fetal echo hydrops 6/51 (12) 6/47 (13)
Pacemaker requirement 38/54 (70) 32/48 (67)
Number of weeks after birth of pacemaker 0.43 (0.14-1.29) 0.57 (0-1.36)
Receiving cardiac meds at follow-up 7/44 (16) 4/40 (10)
Age (yrs) at follow-up 6.0  5.3 4.1  3.8
Child death 1 (2) 4 (7)
Values are n (%), n/N (%), mean  SD, or median (interquartile range). *Comparison of asymptomatic/UAS and all other maternal diagnoses combined in known cases.
Cardiac meds ¼ use of beta-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or digoxin; DCM ¼ dilated cardiomyopathy; echo ¼ echocardiography;
EFE ¼ endocardial ﬁbroelastosis; GA ¼ gestational age; IVIg ¼ intravenous immunoglobulin; IQR ¼ interquartile range; NL ¼ neonatal lupus; SLE ¼ systemic lupus erythematosus;
SS ¼ Sjögren’s syndrome; UAS ¼ undifferentiated autoimmune syndrome.
TABLE 3 Cord Blood Biomarkers Associated With Cardiac NL
Biomarker Cardiac NL Unaffected
OR, OR per SD
(95% CI)
CRP, mg/l 0.35 (0.25-1.00) (48) 0.23 (0.12-0.48) (60) 1.50, 1.78* (LT)
(0.93-2.41)
NT-proBNP, pg/ml 467.8 (34.3-930.5) (55) 165.2 (34.3-295.2) (63) 1.49, 1.76† (LT)
(1.02-2.18)
MMP-2, ng/ml 447.2  144.4 (35) 325.1  170.4 (28) 1.01, 2.36†
(1.30-23.24)
uPA, ng/ml 3.38  0.66 (27) 1.93  0.48 (22) 62.2, 46.61‡
(6.71-577.47)
uPAR, ng/ml 6.57  1.37 (27) 2.07  1.58 (22) 4.01, 41.98‡
(1.94-8.28)
Plasminogen, ng/ml 448.9  215.5 (27) 231.4  102.8 (22) 1.01, 15.68‡
(2.12-83.31)
Values are median (interquartile range) (n) or mean  SD (n), unless otherwise indicated. *p < 0.10. †p < 0.05.
‡p < 0.01. Covariates were: CRP (ﬂuorinated steroid exposure, ﬂuorinated steroid exposure at time of birth,
maternal IVIg, maternal hydroxychloroquine, maternal nonﬂuorinated steroid, sex, week of delivery); NT-proBNP
(ﬂuorinated steroid exposure at birth, maternal IVIg, maternal hydroxychloroquine, gestational age 20 weeks
during winter, week of delivery); MMP-2 (maternal ﬂuorinated steroid, maternal diagnosis of SLE or SS, sex);
uPA (no confounders selected on the basis of p < 0.2); uPAR (no confounders selected on the basis of p < 0.2);
and plasminogen (maternal hydroxychloroquine, maternal nonﬂuorinated steroid, Caucasian race, week of
delivery).
CRP ¼ C-reactive protein; IQR ¼ interquartile range; LT ¼ log-transformed; MMP-2 ¼ matrix
metalloproteinase-2; MV ¼ multivariate; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; OR ¼ odds ratio
per the unit increase of log-transformed value (or original value for uPA/uPAR); OR per SD ¼ odds ratio per the
increase of SD of log-transformed value (or original value for uPA/uPAR); uPA ¼ urokinase plasminogen activator;
uPAR ¼ urokinase plasminogen activator receptor; other abbreviations as in Table 1.
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933univariate and multivariate analyses (regression co-
efﬁcient [RC]: 2.18, p ¼ 0.02 and 1.94, p ¼ 0.02,
respectively) (Figure 1A).
There were no statistical differences between
average maternal CRP levels during 48 cardiac NL and
60 unaffected pregnancies (26.4 mg/l [interquartile
range (IQR): 12.3 to 45.2 mg/l] and 19.5 mg/l [IQR: 9.2
to 42.0 mg/l], respectively). Moreover, there were no
statistical differences between maternal CRP levels
when analyses were limited to GA 16 to 24 weeks in
16 cardiac NL pregnancies and in 38 unaffected
pregnancies (14.1 mg/l [IQR: 11.4 to 34.7 mg/l] and
17.3 mg/l [IQR: 10.6 to 28.7 mg/l], respectively).
No associations with cord or maternal blood CRP
were identiﬁed with extranodal disease, pacemaker
requirement, age at pacemaker placement, need for
cardiac medications on follow-up, or child death.
NT-proBNP AND TROPONIN I. Median cord NT-
proBNP levels were higher in cardiac NL cases than
in unaffected fetuses (Table 3). Log cord NT-proBNP
level was positively associated with cardiac NL in
univariate (OR: 1.59; OR per SD: 1.93; p ¼ 0.001) and
CENTRAL ILLUSTRATION Biomarkers in Cardiac Neonatal Lupus: Association of Cord Blood Biomarkers With
Cardiac-Neonatal Lupus Development
Saxena, A. et al. J Am Coll Cardiol. 2015; 66(8):930–9.
Multivariate associations of serum biomarkers in anti-SSA/Ro-exposed cord blood of cardiac NL and unaffected fetuses. (A) log CRP; (B) log NT-proBNP; (C) troponin I
(ng/ml); (D) MMP-2 (ng/ml). Covariates were: CRP (ﬂuorinated steroid exposure, ﬂuorinated steroid exposure at the time of birth, maternal IVIg, maternal hydroxy-
chloroquine, maternal nonﬂuorinated steroid, sex, week of delivery), NT-proBNP (ﬂuorinated steroid exposure at birth, maternal IVIg, maternal hydroxychloroquine,
gestational age of 20 weeks during winter, and week of delivery), and MMP-2 (maternal ﬂuorinated steroid, maternal diagnosis of SLE or SS, sex). CRP ¼ C-reactive
protein; IVIg ¼ intravenous immunoglobulin; MMP-2 ¼ matrix metalloproteinase-2; NL ¼ neonatal lupus; NT-pro-BNP ¼ N-terminal pro-B-type natriuretic peptide;
SLE ¼ systemic lupus erythematosus.
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934multivariate (OR: 1.49; OR per SD: 1.76; p ¼ 0.04)
analysis (Central Illustration). NT-proBNP was partic-
ularly high in 6 cases with hydrops. However, the
association with cardiac NL remained signiﬁcant,
excluding those cases (OR: 1.54; OR per SD: 1.83;
p ¼ 0.003 univariate; and OR: 1.48; OR per SD: 1.73;
p ¼ 0.04 multivariate). Log cord NT-proBNP was
associated with severity score in univariate and
multivariate analyses (RC: 2.79; p ¼ 0.002; and 1.83;
p ¼ 0.07, respectively) (Figure 1B). No associations
were identiﬁed between NT-proBNP and extranodal
disease or postnatal outcomes.
Mean troponin I concentration was 0.070  0.02
ng/ml in cardiac NL and 0.072  0.02 ng/ml in unaffected
cord bloods (not signiﬁcant) (Central Illustration). No sig-
niﬁcant associations were identiﬁed between troponin I
and extranodal disease, postnatal outcomes, or severity
score.MATRIX METALLOPROTEINASE-2. Mean cord MMP-2
levels were signiﬁcantly associated with cardiac NL in
univariate (OR: 1.01; OR per SD: 2.39; p ¼ 0.006) and
multivariate (OR: 1.01; OR per SD: 2.36; p ¼ 0.03)
analyses (Table 3, Central Illustration), and with
severity score in univariate and multivariate
analyses (RC: 1.01; p ¼ 0.01; and RC: 1.01; p ¼ 0.03,
respectively) (Figure 1C). Cord MMP-2 was not
associated with extranodal disease or postnatal
outcomes.
uPA, uPAR, AND PLASMINOGEN. Elevated cord
blood levels of uPA, uPAR, and plasminogen have
previously been associated with cardiac NL in uni-
variate analysis (17). In multivariate analysis of the
same samples, cord uPA (OR: 62.2; OR per SD: 46.61;
p < 0.001), uPAR (OR: 4.01; OR per SD: 41.98;
p < 0.001), and plasminogen (OR: 1.01; OR per
SD: 15.68; p ¼ 0.004) remained associated with
FIGURE 1 Association of Cord Blood Biomarkers With Cardiac-NL Morbidity
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Multivariate associations of serum biomarkers in anti-SSA/Ro-exposed cord blood with cardiac- NL morbidity derived from a severity score of potential clinical outcomes.
(A) Log CRP; (B) log NT-proBNP; (C) MMP2 (ng/ml); (D) uPA (ng/ml); (E) uPAR (ng/ml); (F) plasminogen (ng/ml). Covariates were: CRP (ﬂuorinated steroid exposure,
ﬂuorinated steroid exposure at time of birth, maternal IVIg); NT-proBNP (ﬂuorinated steroid exposure at birth, maternal hydroxychloroquine, gestational age 20 weeks
during winter, week of delivery); MMP2 (maternal ﬂuorinated steroid, maternal hydroxychloroquine, gestational age 20 weeks during winter); uPA (ﬂuorinated steroid,
maternal IVIg, maternal nonﬂuorinated steroid, sex, gestational age 20 weeks during winter, week of delivery); uPAR (ﬂuorinated steroid, maternal IVIg, maternal non-
ﬂuorinated steroid, maternal diagnosis of SLE or SS, sex, gestational age 20 weeks during winter, week of delivery). Plasminogen (maternal IVIg, maternal nonﬂuorinated
steroid, sex, gestational age 20weeks during winter). SS¼ Sjögren’s syndrome; uPA¼ urokinase plasminogen activator; uPAR¼ urokinase plasminogen activator receptor.
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935cardiac NL versus unaffected cases. uPA, uPAR, and
plasminogen levels were also positively associated
with severity score. RC values in univariate and
multivariate analyses for uPA were 33.7 (p < 0.01) and
10.5 (p ¼ 0.005), respectively; 3.72 (p < 0.001)and 3.13 (p < 0.001) for uPAR, respectively; and
1.01 (p ¼ 0.01) and 1.01 (p ¼ 0.07) for plasmi-
nogen, respectively (Figures 1D to 1F). No additional
associations with extranodal disease or postnatal
outcomes were observed.
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936VITAMIN D. There were no signiﬁcant differences
in cord blood levels of 25(OH) vitamin D between
cardiac NL and unaffected fetuses (23.8  8.2 ng/ml
vs. 22.7  8.3 ng/ml, respectively). Likewise, there
were no associations between concentrations of cord
vitamin D and extranodal disease, postnatal outcome,
or severity score.
The maternal level of vitamin D was analyzed in the
average of all samples available for each pregnancy, as
well as in blood drawn at GA 16 to 24 weeks. In both
cases, levels did not distinguish between cardiac NL
and unaffected pregnancies. The average vitamin D
concentration was 33.5  11.0 ng/ml in cardiac NL and
33.5  13.6 ng/ml in unaffected cases. Vitamin D at GA
16 to 24 weeks was 37.7  10.9 ng/ml in cardiac NL and
36.6  17.1 ng/ml in unaffected cases. Maternal
vitamin D at GA 16 to 24 weeks was lower in 5 cases
with EFE than in 10 cardiac NL cases without EFE
(28.8  8.6 vs. 42.4  9.8, respectively, OR: 0.81; OR
per SD: 0.04; p ¼ 0.08) in univariate analysis only.
Although levels of maternal vitamin D were not asso-
ciated with pacemaker requirement, higher average
levels of maternal vitamin D during pregnancy were
associated with later age of pacemaker placement
in univariate and multivariate analyses (RC: 3.53;
p ¼ 0.008 in both analyses) (Figure 2). There were no
further associations between maternal vitamin D and
other postnatal outcomes or severity score.
DISCUSSION
Data from the largest biorepository to date of
neonates exposed to maternal anti-SSA/Ro anti-
bodies support tissue inﬂammation and ﬁbrosis in
the pathogenesis and morbidity of cardiac NL.tion of Maternal 25(OH) Vitamin D With Age at
nt
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ker placement.Speciﬁcally, cord blood CRP, NT-proBNP, MMP-2,
uPA, uPAR, and plasminogen levels were higher in
neonates with cardiac NL than in unaffected neonates
on multivariate analyses (Table 3) and correlated with
a disease severity score derived from previously
identiﬁed risk factors for mortality. Associations were
independent of maternal rheumatic disease, season
at highest risk of cardiac NL development, and med-
ications during pregnancy. Cord troponin I levels did
not differ between groups. Although vitamin D levels
in cord blood and maternal blood during pregnancy
were equivalent in cardiac NL and unaffected preg-
nancies, higher maternal vitamin D during pregnancy
was associated with a later age of pacemaker im-
plantation in multivariate analysis.
Cord blood CRP elevations have been previously
associated with neonatal sepsis and hypoxia (11,12,29).
This study is the ﬁrst to identify a fetal acute phase
response to passively acquired autoimmunity. The
absence of a signiﬁcant association between maternal
CRP and cardiac NL, paired with the fact that CRP
does not cross the placenta, demonstrates that the
fetus speciﬁcally generates the acute phase response.
The contribution of CRP to the pathogenesis of
cardiac NL is supported by in vitro and in vivo ob-
servations. In adult heart disease, CRP polarizes
macrophages to an inﬂammatory M1 phenotype (30).
Aside from the liver, CRP is also produced by mac-
rophages located within atherosclerotic plaques (31).
In autopsies of cardiac NL fetuses, macrophages have
been persistently identiﬁed in the region of cardiac
conduction tissue (32). Coculture of macrophages
with anti-SSA/Ro opsonized apoptotic cardiocytes
resulted in release of proinﬂammatory and proﬁ-
brosing cytokines that differentiated cardiac ﬁb-
roblasts into scarring phenotypes (33). In addition
to being part of a general inﬂammatory response,
elevated CRP in cardiac NL may play a pathogenic role
in disease development and severity, both as a
marker of inﬁltrating macrophages in cardiac NL tis-
sue and by its action on the macrophages to promote
an inﬂammatory phenotype.
NT-proBNP elevation in cord blood has previously
been correlated with volume overload in neonates
with congenital heart defects (13). In adults, higher
BNP after myocardial infarction is associated with
adverse left ventricular remodeling (34). The ﬁnding
of elevated NT-proBNP in cardiac NL is consistent
with the heart dysfunction that occurs and may be
associated with the further development of heart
abnormalities due to abnormal remodeling. Amniotic
ﬂuid NT-proBNP has been correlated with echocar-
diography in twin-twin transfusion syndrome and has
been proposed as a marker for fetal cardiac health
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937(14,35). Because fetal echocardiograms may underes-
timate pathologic ﬁndings in cardiac NL (36), a sen-
sitive method to predict clinical manifestations in
utero, such as amniotic ﬂuid NT-proBNP, could pro-
vide utility in guiding and monitoring treatment of
cardiac NL.
Cord troponin I was not associated with cardiac NL
or morbidity. It is possible that necrosis of tissue that
precedes cardiomyocyte calciﬁcation occurs only
during the target GA of disease onset, and troponin I
levels may normalize by the time of childbirth.
Alternatively, the troponin I assay used may not have
been sufﬁciently sensitive to detect smaller differ-
ences due to heart failure or myocarditis that novel
high-sensitivity tests would potentially discern.
MMP-2 is a proinﬂammatory and proﬁbrotic mem-
ber of a family of zinc- and calcium-dependent en-
dopeptidases. It is expressed by macrophages and
ﬁbroblasts undergoing transition to myoﬁbroblasts.
Increased MMP-2 has been associated with cardiac
ﬁbrosis in animals and heart failure in adults (16,37).
MMP-2 activates TGF-b, which has been identiﬁed in
the extracellular ﬁbrous matrix of AV nodal regions in
cardiac NL (3). MMP inhibitors decrease ﬁbrosis and
attenuate ventricular dysfunction and remodeling in
dogs with chronic heart failure (38). Thus, MMP in-
hibitors could be a novel therapeutic option to regu-
late antibody-induced inﬂammation and ﬁbrosis in
cardiac NL, as well as to potentially inﬂuence the
remodeling of the fetal heart after the initial insult.
MMP-2 is activated by plasmin, the end product of
the uPA/uPAR/plasminogen pathway, induced by
macrophage accumulation in cardiac tissues (37).
Studies by Briassouli et al. (4,17) revealed that
uPA/uPAR inhibition attenuated TGF-b activation in
supernatants of apoptotic cardiocytes exposed to
anti-SSA/Ro and that cord blood uPA, uPAR, and
plasminogen were elevated in cardiac NL cases in
univariate analysis (4,17). In applying multivariate
analysis to the previously reported results, uPA,
uPAR, and plasminogen remained signiﬁcantly asso-
ciated with development of cardiac NL and associated
with disease severity. These ﬁndings reinforce the
role of this proﬁbrotic pathway in cardiac NL, which
could also be a new target for treatment.
Vitamin D has become a topic of interest in au-
toimmunity and cardiac disease, as its numerous
immunomodulatory effects inﬂuence both innate and
adaptive mechanisms (39). Low levels of vitamin D
have been reported in autoimmune diseases, in-
cluding SLE and scleroderma (40,41). Vitamin D re-
ceptor signaling is impaired in scleroderma, and
reduced receptor expression with decreased vitamin D
levels enhances the sensitivity of sclerodermaﬁbroblasts to the proﬁbrotic effects of TGF-b (18).
Animal studies indicate that vitamin D deﬁciency can
result in cardiac inﬂammation, ﬁbrosis, apoptosis,
and systolic dysfunction (19). In a Swedish NL cohort,
a season-of-birth pattern was reported in which GA of
18 to 24 weeks occurring in winter correlated with a
higher proportion of children with cardiac NL (10).
This led the authors to hypothesize that low maternal
vitamin D in winter months may contribute to dis-
ease development. In the present study, there were
no differences in season of gestational vulnerability
or vitamin D level in cord or maternal bloods between
cardiac NL and unaffected cases. In a small subgroup
of cardiac NL cases with maternal blood obtained
during GA 16 to 24 weeks, a negative trend in vitamin D
with development of EFE was noted on univariate
analysis. Among patients requiring a pacemaker,
higher maternal vitamin D was associated with later
age of placement on multivariate analysis. Given the
known role of TGF-b in cardiac NL, there remains
reason to consider vitamin D as a potential modiﬁable
risk factor in disease morbidity, and further study is
warranted.
The association of our studied analytes with
severity of cardiac NL underscores their potential
clinical utility as biomarkers to identify and treat
sicker cases. Furthermore, a recent report from
the Swedish cardiac NL cohort identiﬁed 13 anti-SSA/
Ro-exposed cases diagnosed after birth (age 4 months
to 43 years of age), 11 with normal heart rates in
utero (42). These ﬁndings support the hypothesis that
immune-mediated inﬂammation and ﬁbrosis in car-
diac tissues can continue postnatally, resulting in late
progression to cardiac NL. Accordingly, biomarkers
may be important monitoring tools for anti-SSA/
Ro-exposed infants to identify those at risk for late
disease progression.
STUDY LIMITATIONS. This study represents the
largest reported cohort of anti-SSA/Ro-exposed
pregnancies with available cord and maternal blood,
but several limitations are acknowledged. The sample
size remains a shortcoming in the investigation of
prospective biomarkers in cardiac NL. Due to the
rarity of the disease and ﬁnite quantities of available
blood, not all analytes could be measured in each
sample, and the GA at sampling also varied among
cases. Rates of highly negative outcomes, such as
extranodal disease, use of postnatal cardiac medica-
tions, and death are often <10%, limiting the power to
signiﬁcantly identify differences in biomarkers be-
tween groups. Blood from the most severe cases
resulting in death in utero were also not available for
study. Furthermore, fetal echocardiographic data was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Inﬂammation and ﬁbrosis are central to the patho-
genesis of cardiac complications of neonatal lupus.
Several related biomarkers in the cord blood of
affected fetuses are associated with disease severity.
TRANSLATIONAL OUTLOOK: Future studies
should examine the value of biomarkers of inﬂam-
mation as surrogates for progressive cardiac
dysfunction in the evaluation of antiﬁbrotic thera-
peutic strategies for treating affected individuals.
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938unavailable in 15% of all pregnancies. The RRNL is a
U.S.-based registry and despite nearly universal pre-
natal vitamin therapy, enrollees can have a wide
range of sun exposure within various climates
throughout the country. Furthermore, differing clin-
ical practices amongst the various sites may limit the
interpretation of timing of pacemaker placement.
These factors may have had undocumented effects on
associations with maternal vitamin D levels, com-
pared to the more homogeneous Swedish cohort.
CONCLUSIONS
CRP and NT-proBNP in cord blood are signiﬁcantly
associated with development and severity of cardiac
NL and can be considered markers to identify wors-
ening heart function after birth. Elevations of MMP-2,
uPA, uPAR, and plasminogen suggest therapies
aimed at decreasing ﬁbrosis. The role of vitamin D is
unclear, but optimizing maternal levels could become
routine in the management of all anti-SSA/Ro-
positive pregnancies.
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